Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$56.70
neg -2.20
-3.70%
Today's Range: 56.21 - 57.91 | TEVA Avg Daily Volume: 5,837,500
Last Update: 02/08/16 - 1:53 PM EST
Volume: 6,043,327
YTD Performance: -10.33%
Open: $57.89
Previous Close: $58.86
52 Week Range: $54.17 - $72.31
Oustanding Shares: 852,000,000
Market Cap: 51,034,800,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 10 10
Moderate Buy 2 2 2 2
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 1
Mean Rec. 1.56 1.56 1.59 1.79
Latest Dividend: 0.29
Latest Dividend Yield: 1.94%
Dividend Ex-Date: 11/13/15
Price Earnings Ratio: 40.20
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
40.20 29.00 30.32
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.38% 2.29% 55.96%
GROWTH 12 Mo 3 Yr CAGR
Revenue -0.20 0.11 0.03
Net Income 142.80 0.10 0.03
EPS 138.50 0.15 0.05
Earnings for TEVA:
EBITDA 6.00B
Revenue 20.27B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $1.28 $1.48 $5.34 $5.68
Number of Analysts 4 1 7 6
High Estimate $1.29 $1.48 $5.37 $6.03
Low Estimate $1.27 $1.48 $5.25 $5.30
Prior Year $1.31 $1.36 $5.07 $5.34
Growth Rate (Year over Year) -2.29% 8.82% 5.27% 6.39%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Mylan and Endo International look like bargains at current prices.
History indicates pharmaceutical companies with low multiples offer payoffs down the road.
Look for 2015's record run of mergers and acquisitions to continue.
They are a diverse group that could work well as a basket.
The combined company will provide lots of opportunities.
These two will continue to churn out earnings growth.
We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.
Markets were slightly up on the open, but I wouldn't be surprised to see some profit-taking today after Wall Street started November with two big days of gains.
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
Reports of merger talks have been confirmed, and we believe the two pharma giants would both benefit from the deal.

Columnist Conversations

Usual semi-annual testimony before the House Financial Services Committee on Wednesday and Thursday Caveat Em...
I've owned most of the names I mentioned for a long time. I was buying Apple back in 2003, as noted here on Re...
Brutal start to another week in what has been abysmal start to 2016. I think all you can do is to incrementa...
Keeping on Best Ideas List but in light of 11% price drop since Thursday's close, covering alot.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.